Addex Therapeutics Ltd

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025